Cargando…
Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry
Background: Moderate and high efficacy disease modifying therapies (DMTs) have a profound effect on disease activity. The current treatment guidelines only recommend high efficacy DMTs for patients with highly active MS. The objective was to examine the impact of initial treatment choice in achievin...
Autores principales: | Simonsen, Cecilia Smith, Flemmen, Heidi Øyen, Broch, Line, Brunborg, Cathrine, Berg-Hansen, Pål, Moen, Stine Marit, Celius, Elisabeth Gulowsen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248666/ https://www.ncbi.nlm.nih.gov/pubmed/34220694 http://dx.doi.org/10.3389/fneur.2021.693017 |
Ejemplares similares
-
The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression
por: Simonsen, Cecilia Smith, et al.
Publicado: (2020) -
Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population
por: Simonsen, Cecilia Smith, et al.
Publicado: (2022) -
The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis
por: Simonsen, Cecilia Smith, et al.
Publicado: (2020) -
High prevalence of fatigue in contemporary patients with multiple sclerosis
por: Broch, Line, et al.
Publicado: (2021) -
Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
por: Simonsen, Cecilia Smith, et al.
Publicado: (2016)